Menu
Search
|

Menu

Close
X

Array Biopharma Inc ARRY.OQ (NASDAQ Stock Exchange Global Market)

22.90 USD
+0.41 (+1.82%)
As of 3:57 PM EDT
chart
Previous Close 22.49
Open 22.49
Volume 436,358
3m Avg Volume 1,009,327
Today’s High 22.98
Today’s Low 22.22
52 Week High 24.75
52 Week Low 12.58
Shares Outstanding (mil) 218.21
Market Capitalization (mil) 4,907.62
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.64 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY19
139
FY18
174
FY17
151
FY16
138
EPS (USD)
FY19
-0.170
FY18
-0.746
FY17
-0.718
FY16
-0.649
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.10
Price to Sales (TTM)
vs sector
20.34
8.84
Price to Book (MRQ)
vs sector
17.17
4.60
Price to Cash Flow (TTM)
vs sector
--
40.07
Total Debt to Equity (MRQ)
vs sector
46.49
17.66
LT Debt to Equity (MRQ)
vs sector
46.49
13.97
Return on Investment (TTM)
vs sector
-26.11
12.12
Return on Equity (TTM)
vs sector
-42.26
13.24

EXECUTIVE LEADERSHIP

Carrie Cox
Independent Chairman of the Board, Since 2018
Salary: --
Bonus: --
Ron Squarer
Chief Executive Officer, Director, Since 2012
Salary: $615,760.00
Bonus: $473,582.00
Jason Haddock
Chief Financial Officer, Since 2016
Salary: $377,770.00
Bonus: $193,375.00
Andrew Robbins
Chief Operating Officer, Since 2015
Salary: $446,456.00
Bonus: $257,528.00
Nicholas Saccomano
Chief Scientific Officer, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3200 Walnut St
BOULDER   CO   80301-2514

Phone: +1303.3816600

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

SPONSORED STORIES